Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study

Abstract

In the present study, we investigate the outcome of 109 Danish and 123 Swedish patients with nodal PTCL in first complete remission (CR), and examine the impact of imaging-based follow-up (FU) strategies. The patients were selected by the following criteria: (a) newly diagnosed nodal PTCL from 2007 to 2012, (b) age ≥18 years, and (c) CR after CHOP or CHOEP therapy. FU guidelines in Sweden included symptom assessment, clinical examinations and blood tests at 3-4-month intervals for 2 years. FU strategies in Denmark was similar but included routine imaging, usually every 6 months for 2 years. Patients had fully comparable characteristics. Overall survival (OS) estimates for patients in CR were similar for all patients (p = .6) and in PTCL subtypes. In multivariate analysis, country of follow-up had no impact on OS. However, despite continuous CR for ≥2 years, the OS of PTCL remained inferior to a matched general population.

Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study

“…The databases across the variables described are remarkably concordant, and even the OS curves of the populations are similar to that described from other international registries (17,18). First, the data confirm that those patients receiving pralatrexate earlier exhibit superior benefit as measured by ORR, CR, DOR, and PFS.…”

UK Guidelines on the Diagnosis and Treatment of Breast Implant‐Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group

“…While clinical assessment is required, there is a lack of evidence to support routine imaging surveillance of BIA-ALCL whether limited or advanced stage. 86,87 This is analogous to the clinical principles that guide surveillance in other NHL subtypes, that routine imaging does not improve patient outcomes. [88][89][90] Our recommendation takes into consideration evidence from a range of lymphoma subtypes, the American Society of Hematology Choosing Wisely Campaign 91 and surveillance guidance provided by the NICE guidelines on NHLs.…”

“…We advocate joint patient follow‐up between the surgical and haemato‐oncology teams every 3–6 months, for a minimum of two years and then as indicated. While clinical assessment is required, there is a lack of evidence to support routine imaging surveillance of BIA‐ALCL whether limited or advanced stage 86,87 . This is analogous to the clinical principles that guide surveillance in other NHL subtypes, that routine imaging does not improve patient outcomes 88–90 .…”

Routine imaging for disease surveillance in follicular lymphoma—To comfort the patients or their doctors?

“…The results have been mixed; some studies have reported trends toward better outcomes, but most have not 7,8,10,17 . Other types of studies have compared survival outcomes in large patient populations exposed to different disease surveillance strategies and found comparable outcomes with or without imaging 6,18 …”